IH
ALXN

IFC Holdings’s Alexion Pharmaceuticals ALXN Stock Holding History

IFC Holdings’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-6,144
Closed -$861K – 547
2017
Q3 		$861K Buy
+6,144
New +$835K 0.06% 210
2016
Q1 		– Sell
-8,426
Closed -$1.6M – 411
2015
Q4 		$1.6M Buy
8,426
+1,129
+15% +$197K 0.21% 84
2015
Q3 		$1.09M Sell
7,297
-339
-4% -$61.8K 0.17% 105
2015
Q2 		$1.41M Sell
7,636
-414
-5% -$71.4K 0.2% 102
2015
Q1 		$1.46M Buy
8,050
+350
+5% +$63.4K 0.22% 98
2014
Q4 		$1.44M Buy
7,700
+1,116
+17% +$207K 0.24% 92
2014
Q3 		$1.09M Sell
6,584
-15
-0.2% -$2.46K 0.2% 108
2014
Q2 		$1.04M Sell
6,599
-205
-3% -$32.4K 0.19% 109
2014
Q1 		$1.02M Sell
6,804
-1,065
-14% -$169K 0.21% 99
2013
Q4 		$1.03M Hold
7,869
– – 0.22% 108
2013
Q3 		$912K Buy
7,869
+258
+3% +$28.3K 0.2% 122
2013
Q2 		$700K Buy
+7,611
New +$733K 0.17% 152

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

IFC Holdings's ALXN Position: Q4 2017 in Review

IFC Holdings sold out of Alexion Pharmaceuticals (ALXN) in Q4 2017, closing a stake of 6,144 shares — an estimated $861K sold.

IFC Holdings first reported a position in ALXN in Q2 2013 and held it in 12 quarters. The position peaked at $1.6M in Q4 2015. 587 funds tracked by Wall St. Rank hold ALXN as of Q4 2017.

  • IFC Holdings reported no remaining Alexion Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • IFC Holdings sold 6,144 Alexion Pharmaceuticals shares in Q4 2017, an estimated $861K.
  • IFC Holdings first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 12 quarters.
  • IFC Holdings's Alexion Pharmaceuticals position peaked at $1.6M in Q4 2015.
  • 587 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2017.

Based on IFC Holdings's 13F filing for Q4 2017, filed 31 Jan 2018.